TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection.
T lymphocytes
chronic viral hepatitis
hepatitis B
immune response
Journal
Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R
Informations de publication
Date de publication:
23 Oct 2020
23 Oct 2020
Historique:
received:
30
06
2020
revised:
22
09
2020
accepted:
24
09
2020
entrez:
24
10
2020
pubmed:
25
10
2020
medline:
25
10
2020
Statut:
aheadofprint
Résumé
Chronic hepatitis B virus (HBV) infection is characterised by HBV-specific CD8+ T cell dysfunction that has been linked to Tcell exhaustion, a distinct differentiation programme associated with persisting antigen recognition. Recently, Thymocyte Selection-Associated High Mobility Group Box (TOX) was identified as master regulator of CD8+ T cell exhaustion. Here, we addressed the role of TOX in HBV-specific CD8+ T cell dysfunction associated with different clinical phases of infection. We investigated TOX expression in HBV-specific CD8+ T cells from 53 HLA-A*01:01, HLA-A*11:01 and HLA-A*02:01 positive patients from different HBV infection phases and compared it to hepatitis C virus (HCV)-specific, cytomegalovirus (CMV)-specific, Epstein-Barr virus (EBV)-specific and influenza virus (FLU)-specific CD8+ T cells. Phenotypic and functional analyses of virus-specific CD8+ T cells were performed after peptide-loaded tetramer-enrichment and peptide-specific expansion. Our results show that TOX expression in HBV-specific CD8+ T cells is linked to chronic antigen stimulation, correlates with viral load and is associated with phenotypic and functional characteristics of T-cell exhaustion. In contrast, similar TOX expression in EBV-specific and CMV-specific CD8+ T cells is not linked to T-cell dysfunction suggesting different underlying programmes. TOX expression in HBV-specific CD8+ T cells is also affected by targeted antigens, for example, core versus polymerase. In HBV-specific CD8+ T cells, TOX expression is maintained after spontaneous or therapy-mediated viral control in chronic but not self-limiting acute HBV infection indicating a permanent molecular imprint after chronic but not temporary stimulation. Our data highlight TOX as biomarker specific for dysfunctional virus-specific CD8+ T cells in the context of an actively persisting infection.
Identifiants
pubmed: 33097558
pii: gutjnl-2020-322404
doi: 10.1136/gutjnl-2020-322404
pmc: PMC8292571
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Immunity. 2012 Dec 14;37(6):1130-44
pubmed: 23159438
J Clin Invest. 1996 Apr 1;97(7):1655-65
pubmed: 8601631
Hepatology. 2011 May;53(5):1494-503
pubmed: 21360567
Nature. 2019 Jul;571(7764):265-269
pubmed: 31207605
Gut. 2019 May;68(5):905-915
pubmed: 30622109
J Exp Med. 2014 Sep 22;211(10):2047-59
pubmed: 25225458
Gastroenterology. 1999 Dec;117(6):1386-96
pubmed: 10579980
Nat Immunol. 2019 Jul;20(7):890-901
pubmed: 31209400
Science. 2012 Nov 30;338(6111):1220-5
pubmed: 23197535
Gut. 2019 May;68(5):893-904
pubmed: 30580250
Gut. 2019 May;68(5):770-773
pubmed: 30700541
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
J Clin Invest. 2008 May;118(5):1835-45
pubmed: 18398508
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195619
Nat Commun. 2017 May 03;8:15050
pubmed: 28466857
J Virol. 2007 Apr;81(8):4215-25
pubmed: 17287266
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Nature. 2016 Aug 2;537(7620):412-428
pubmed: 27501245
Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4
pubmed: 19800335
J Virol. 2003 Jan;77(1):68-76
pubmed: 12477811
Gastroenterology. 2020 Aug;159(2):652-664
pubmed: 32302614
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
J Clin Invest. 2018 Feb 1;128(2):668-681
pubmed: 29309050
Gastroenterology. 2012 Oct;143(4):963-73.e9
pubmed: 22796241
J Hepatol. 2014 Dec;61(6):1212-9
pubmed: 25016223
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):662-675
pubmed: 31548710
Blood. 2010 May 6;115(18):3718-25
pubmed: 20200354
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Virol. 2004 Jun;78(11):5707-19
pubmed: 15140968
J Virol. 2015 Jan;89(1):25-34
pubmed: 25320295
Nat Med. 2017 Mar;23(3):327-336
pubmed: 28165481
Sci Immunol. 2020 Jul 3;5(49):
pubmed: 32620560